Welcome to our dedicated page for Arcus Bioscience SEC filings (Ticker: RCUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arcus Biosciences, Inc. (NYSE: RCUS) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company focused on oncology and inflammatory and autoimmune diseases, Arcus uses SEC filings to report material clinical, financial and corporate events that can be important for investors analyzing RCUS stock.
Form 8‑K current reports frequently highlight significant developments in Arcus’s pipeline and capital structure. For example, 8‑K filings describe the discontinuation of the Phase 3 STAR‑221 trial and the Phase 2 EDGE‑Gastric study after an interim overall survival analysis showed no benefit for the domvanalimab plus zimberelimab and chemotherapy regimen compared with nivolumab plus chemotherapy. Other 8‑Ks detail updated data from the ARC‑20 Phase 1/1b study of casdatifan in metastatic clear cell renal cell carcinoma, including progression-free survival and response metrics, as well as safety findings.
Filings also cover financing and capital markets transactions. One Form 8‑K outlines an underwriting agreement for a public offering of common stock, including the number of shares sold, pricing and net proceeds. Another 8‑K describes a First Amendment to the company’s Loan and Security Agreement with Hercules Capital and other lenders, which restructures remaining term loan commitments into milestone-based tranches tied to Phase 3 data and potential FDA approval, extends the maturity date and adds performance covenants linked to market capitalization, qualified cash levels and potential net product revenue thresholds.
Investors can also use SEC filings to track collaboration and licensing arrangements, such as disclosures related to Arcus’s long-term collaboration with Gilead Sciences and its option and license agreement with Taiho Pharmaceutical. These documents may reference option exercises, milestone structures and rights to co-develop or commercialize investigational medicines like casdatifan, domvanalimab, zimberelimab and quemliclustat in specific territories.
Stock Titan’s interface surfaces these filings alongside AI-powered summaries that explain the practical implications of each document. Instead of parsing detailed legal language alone, readers can review concise explanations of how a loan amendment changes Arcus’s access to capital, what a trial discontinuation means for a particular program, or how a new data disclosure from a Phase 1/1b or Phase 3 study might influence the company’s development strategy. Real-time updates from EDGAR, combined with these AI insights, help users follow Arcus’s quarterly results, material clinical events, financing decisions and collaboration milestones directly from the underlying SEC record.
Arcus Biosciences (RCUS): Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen filed an amended Schedule 13G reporting beneficial ownership of 4,332,479 Arcus common shares, equal to 4.1% of the class as of September 30, 2025.
The reporting persons have 0 shares with sole voting or dispositive power and 4,332,479 shares with shared voting and shared dispositive power. They certified the holdings were not acquired with the purpose or effect of changing or influencing control.
Arcus Biosciences (RCUS) reported an insider transaction by its Chief Operating Officer. On 11/07/2025, the officer exercised 50,291 stock options at $1.2276 per share and sold 50,291 common shares at a $18.9709 weighted average price under a Rule 10b5-1 trading plan. After these trades, the officer directly held 214,232 common shares. The filing notes the sales occurred across multiple trades between $18.59 and $19.42. Remaining derivative holdings include 80,583 stock options with an expiration date of 03/14/2027.
Gilead Sciences filed Amendment No. 6 to its Schedule 13D on Arcus Biosciences, updating its beneficial ownership and voting power disclosures. Gilead reports beneficial ownership of 31,424,760 shares of Arcus common stock, representing 25.6% of the class. Gilead has sole voting and dispositive power over the same 31,424,760 shares and no shared power.
The percentage is based on 122,856,086 shares outstanding as reported in a prospectus supplement dated October 31, 2025. The filing details prior purchases under multiple purchase agreements and offerings. It also notes that Jeffrey A. Bluestone holds options exercisable within 60 days for 10,750 shares, equating to 0.01% on an as‑converted basis.
Arcus Biosciences (RCUS): The company’s President reported an open‑market sale of 4,314 shares of common stock on 10/30/2025 at a weighted average price of $20.3175, executed under a Rule 10b5‑1 trading plan adopted on August 12, 2024.
Following the transaction, the reporting person beneficially owned 1,087,060 shares indirectly (by trust) and 367,220 shares directly. The price reflected multiple trades between $20.12 and $20.63.
Arcus Biosciences (RCUS) completed an underwritten public offering of common stock. The company sold 15,755,000 shares, including the full exercise of the underwriters’ 2,055,000-share option, and received net proceeds of approximately $269.7 million after discounts and expenses.
The shares were offered at a public price of $18.25 per share, with underwriters purchasing at $17.155 per share. The transaction was conducted under an effective Form S-3 registration, with Leerink Partners LLC and Goldman Sachs & Co. LLC acting as representatives of the underwriters. The offering closed on November 3, 2025.
Arcus Biosciences (RCUS) launched a primary offering of 13,700,000 shares of common stock at $18.25 per share. The transaction is expected to generate gross proceeds of $250,025,000, less underwriting discounts of $15,001,500, for proceeds to the company before expenses of $235,023,500. Arcus also granted the underwriters a 30‑day option to purchase up to 2,055,000 additional shares.
Arcus estimates net proceeds of approximately $234.5 million (or approximately $269.7 million if the option is exercised in full). The company plans to use the funds to advance R&D, including expansion of the casdatifan program and development of immunology and inflammation candidates, and for general corporate purposes. Based on 107,101,086 shares outstanding as of September 30, 2025, new investors would face an immediate dilution of $12.70 per share at the offering price. A 60‑day lock‑up applies to the company and insiders, subject to customary exceptions. The shares are expected to be delivered on or about November 3, 2025.
Arcus Biosciences (RCUS) holder filed a Form 144 to sell 1,173 shares of Class A Common Stock with an aggregate market value of $23,682.87, approximately on October 30, 2025, through Goldman Sachs & Co. LLC on the NYSE.
The notice also lists recent sales by the same account: 19,019 shares for $383,944.16 on October 28, 2025; 76,667 shares for $1,600,791.63 on October 29, 2025; 1,173 shares for $25,844.94 on October 29, 2025; and 3,141 shares for $63,817.27 on October 30, 2025. Shares outstanding were 107,973,536; this is a baseline figure, not the amount being sold.
Arcus Biosciences plans a primary offering of common stock under its effective shelf registration. Leerink Partners and Goldman Sachs are joint bookrunners, and the company expects to grant a 30‑day option to the underwriters to purchase additional shares. Arcus’s common stock trades on the NYSE under “RCUS”; the last reported sale price was $20.29 on October 29, 2025.
The company states that net proceeds will fund ongoing research and development, including expansion of the casdatifan (HIF‑2α) clinical program, discovery and development in its immunology and inflammation portfolio, and for general corporate purposes such as working capital and operating expenses. A 60‑day lock‑up applies to the company and certain insiders, subject to customary exceptions.
Shares outstanding were 107,101,086 as of September 30, 2025; this is a baseline figure, not the amount being offered.
Arcus Biosciences (RCUS) reported insider transactions by its President. On 10/28/2025, an indirect trust sold 19,019 shares at a weighted average price of $20.1874 (range $20.00–$20.36). On 10/29/2025, the trust sold 47,675 shares at $20.4894 (range $20.00–$20.99), 29,365 shares at $21.5279 (range $21.02–$22.01), and 800 shares at $22.0441 (range $22.035–$22.055), all pursuant to a Rule 10b5-1 plan adopted on August 12, 2024. Following the reported transactions, beneficial holdings were 1,091,374 shares indirect (by trust) and 367,220 shares direct.
Arcus Biosciences (RCUS) reported an insider transaction by its Chief Financial Officer. On 10/28/2025, the CFO sold 5,000 shares of common stock at $20 per share, coded as an open market sale (S).
Following the transaction, the officer beneficially owns 92,138 shares, held directly. The filing notes the sales were made under a Rule 10b5-1 trading plan adopted on March 7, 2023, which pre-schedules trades.